Canada
· Delayed Price · Currency is CAD MindBio Therapeutics Company Description
MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Australasia.
The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, chronic pain, cognitive impairment, post-traumatic stress disorder, panic disorder, and opiate addictions.
It also establishes and executes research protocols through formal clinical trials that are facilitated via digital therapeutic platforms; and invests in research for developing treatments for depression, anxiety, PTSD and chronic pain.
In addition, the company develops MB22001, which is in Phase 2 clinical trial, for the treatment of major depressive disorder, as well as existential distress, anxiety, and depression associated with advanced stage cancer; and wearable devices to collect biometric data in mental health patients taking psychedelic medicines.
MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Justin Hanka |
Contact Details
Address: 1055 West Georgia Street Vancouver, British Columbia V6E 4N7 Canada | |
| Website | mindbiotherapeutics.com |
Stock Details
| Ticker Symbol | MBIO |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin Adam Hanka | Co Founder, Chief Executive Officer and Director |
| John M. Dinan | Chief Financial Officer |
| Dr. Lahiru Russell Ph.D. | Chief Scientist |